SFA-001N / SFA Therap - LARVOL DELTA

SFA Therapeutics Strengthens Intellectual Property in…Hepatocellular Carcinoma (PRNewswire) - "SFA Therapeutics, Inc...announced the expansion of its intellectual property in...hepatocellular carcinoma. SFA Therapeutics has been issued a new patent in the United States (11963938) and has been allowed two patent applications in Canada (2,974,510) and in Korea (10-2017-7023391) with patent coverage through 2036. SFA Therapeutics has also been issued one new patent in Korea (10-2646764) with patent coverage through 2038. The United States patent and the allowed Canadian and Korean patent applications protect the short chain fatty acid composition that comprises SFA's proprietary oral small-molecule biosynthetic compound SFA-001."

Patent • Hepatocellular Cancer

SFA Therapeutics Announces FDA Clearance of IND Application for SFA-001N for the Treatment of NASH and Fibrosis (PRNewswire) - "SFA Therapeutics...announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to investigate SFA-001N in patients with non-alcoholic steatohepatitis (NASH) with or without fibrosis. SFA-001N is designed to act on multiple pathways involved in the pathogenesis of NASH....In addition to SFA-001N, SFA Therapeutics is investigating SFA-002 in a Phase 1b clinical trial for psoriasis and expects to complete enrollment in early 2023 and share topline data by the end of 2023."

Enrollment status • IND • P1 data • Fibrosis • Immunology • Non-alcoholic Steatohepatitis • Psoriasis